<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389490</url>
  </required_header>
  <id_info>
    <org_study_id>GLARGL08588</org_study_id>
    <nct_id>NCT03389490</nct_id>
  </id_info>
  <brief_title>Toujeo Versus NPH Self-titration Study</brief_title>
  <official_title>A Pilot Study to Describe the Glycaemic Variability of Insulin Glargine 300U/ml Versus NPH (Neutral Protamine Hagedorn) in the Insulin-naïve Type 2 Diabetes Patients Following a Patient-adjusted Insulin Algorithm in Hong Kong</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elaine Chow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 24 week, multicentre, prospective, randomized, controlled, parallel-designed (1:1)
      pilot study.The study will compare glycemic variability in patients treated with insulin
      glargine U300/ml insulin versus conventional (NPH) insulin using a self titration
      algorithm.50 type 2 diabetes patients who are newly started on insulin will be recruited.
      They will be randomly allocated to either insulin glargine U300 or NPH insulin for 26 weeks.
      All subjects will follow a insulin-self titration algorithm. The study will consist of 9
      visits over 26 weeks. Blood glucose variability will be collected by CGM for 7 consecutive
      days at baseline (week -1) and at week 24.Secondary endpoints other than data on glycemic
      variability, including HbA1c, fasting plasma glucose, inflammatory markers will be measured
      during three periods (week 0, week 12 and week 24).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic variability</measure>
    <time_frame>24 weeks</time_frame>
    <description>Standard deviation of glucose from continuous glucose monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean Amplitude of Glycemic excursions and Means of Daily Differences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage time in target</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of time &lt;3.0mmol/L and &gt;10.0mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated haemoglobin</measure>
    <time_frame>24 weeks</time_frame>
    <description>HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>24 weeks</time_frame>
    <description>FPG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycemia</measure>
    <time_frame>24 weeks</time_frame>
    <description>Overall incidence of hypoglycemia and nocturnal hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving HbA1c &lt;7.0%</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients achieving HbA1c &lt;7.0% at week 24 without confirmed hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction</measure>
    <time_frame>24 weeks</time_frame>
    <description>ITSQ questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>24 weeks</time_frame>
    <description>change in hs C reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in heart rate variability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine 300U/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neutral Protamine Hagedorn insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine 300 UNT/ML</intervention_name>
    <description>Self titration of insulin glargine U300</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neutral protamine hagedorn insulin</intervention_name>
    <description>Self titration of NPH insulin</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetic suboptimally controlled on their previous antidiabetic treatment

               -  18 ≤ age ≤ 75

               -  Stable dose of oral antidiabetic treatment for &gt; 8 weeks

               -  The number of OADs that the patients used should be &quot;3&quot; or less

               -  HbA1c level &gt; 7.0% and &lt; 10%

               -  Fasting plasma glucose &gt; 8mmol/L and &lt;15mmol

               -  BMI &lt; 40 kg/m2

               -  Patient who is capable and willing to perform regular SMBG

               -  Patient who is capable and willing for insulin injection

               -  Confirmed written consent

               -  Insulin naïve

        Exclusion Criteria:

          -  Participation in a clinical trial with any investigational drug used with curative
             intent and within 30 days prior to study entry

          -  Patient known to have hypoglycaemia unawareness or recurrent major hypoglycaemia

          -  Any product containing prandial insulin

          -  Concomitant medication known to interface with glucose metabolism (such as systematic
             steroids)

          -  Change in dose of non-insulin anti-diabetic treatment or initiation of new
             anti-diabetic medications in the last 8 weeks prior to screening

          -  Patients treated with steroid or nonsteroidal anti-inflammatory drugs

          -  Patient who had experienced an acute concurrent illness during the 3-month period
             before the investigation

          -  Patient with hepatic disease and end-stage renal disease

          -  Patients unable to comply with follow-up visits

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine Chow</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elaine Chow</last_name>
    <phone>35051549</phone>
    <email>e.chow@cuhk.edu.hk</email>
  </overall_contact>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2017</study_first_submitted>
  <study_first_submitted_qc>December 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>December 26, 2017</last_update_submitted>
  <last_update_submitted_qc>December 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Elaine Chow</investigator_full_name>
    <investigator_title>Dr, Clinical Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

